CVS HEALTH Corp (CVS) Form 10-Q — Aug 5, 2026
CVS Health reported Q2 2026 revenues of $106.1 billion, up 7.3% year over year, with net income attributable to CVS Health of $2.98 billion ($2.31 diluted EPS) versus $1.02 billion ($0.80) a year earlier. Operating income rose 97.5% to $4.7 billion, with revenue growth across all four operating segments. The improvement reflects stronger underlying performance — especially in the Aetna-based Health Care Benefits segment, where the medical benefit ratio fell 250 basis points to 87.4% — plus the absence of $833 million in legacy litigation charges recorded in Q2 2025.
Key figures
- Eps
- 2.31
- Revenue
- 106096000000
- Net Income
- 2979000000
- Total Debt
- $61.4 billion ($59,452 million long-term debt plus $1,958 million current portion)
- Revenue Yoy
- 7.3% (Q2 2026 vs Q2 2025)
- Total Assets
- 253768000000
- Cash Position
- 11329000000
- Shares Outstanding
- 1278970369
- Medical membership
- 26.0 million as of June 30, 2026
- Operating income q2 2026
- $4,703 million (up 97.5% YoY)
- Same store sales q2 2026
- 2.6% total; pharmacy +2.9%; front store +1.0%
- Effective tax rate q2 2026
- 24.7% vs 38.5% prior year
- Prescriptions filled q2 2026
- 457.0 million (+4.3% on 30-day equivalent basis)
- Quarterly dividend per share
- 0.665
- Commercial premiums change q2
- -19.7% YoY following individual exchange exit
- Medical benefit ratio q2 2026
- 87.4% vs 89.9% prior year (-250 bps)
- Remaining buyback authorization
- $11.5 billion ($10.0B 2022 program + $1.5B 2021 program)
- Adjusted operating income q2 2026
- $5,157 million vs $3,808 million prior year (+35%)
- Pharmacy claims processed q2 2026
- 473.0 million
- Premium deficiency reserve q2 2026
- $15 million (one Medicaid state)
- Operating cash flow six months 2026
- $10,594 million (+64.2% YoY)
- Prior year q2 2025 legacy litigation charges
- $833 million
- Cms final 2027 medicare advantage rate increase
- 2.48% industry average
Price after filing
Close on the filing date to close N calendar days later (from $104.42). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.